Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Alternative Names: Anti-EGFR NanomAbs; Anti-H-ferritin NanomAbs; Anti-HER2 NanomAbs; Antibody nanoparticle conjugates - Immune Pharmaceuticals; Monoclonal antibody-nanomedicine conjugates - Immune Pharmaceuticals; Nano-therapeutics - Immune Pharmaceuticals; NanomAbs®

Latest Information Update: 23 Feb 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Pharmaceuticals
  • Developer Immune Pharmaceuticals Ltd
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Cancer in Israel (Parenteral) (STC biologics pipeline, February 2023)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral, Injection)
  • 21 May 2015 Preclinical trials in Cancer in Israel (unspecified route) before May 2015 (Immune Pharmaceuticals pipeline)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top